Reaction
Autoimmune Colitis reporting signals
As of the last recalculation, Autoimmune Colitis appears in 635 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is IPILIMUMAB (PRR 386.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ipilimumab | 283 | 386.9 | 389.4 |
| Nivolumab | 271 | 159.6 | 160.0 |
| Pembrolizumab | 151 | 61.4 | 61.5 |
| Vemurafenib | 15 | 41.9 | 41.9 |
| Atezolizumab | 40 | 36.0 | 36.0 |
| Pemetrexed | 19 | 29.9 | 29.9 |
| Pemetrexed Disodium | 33 | 29.9 | 29.9 |
| Granisetron Hydrochloride | 9 | 28.6 | 28.7 |
| Granisetron | 9 | 28.5 | 28.5 |
| Dabrafenib | 16 | 25.5 | 25.5 |
| Trametinib | 15 | 20.8 | 20.8 |
| Durvalumab | 12 | 19.7 | 19.7 |
| Carboplatin | 66 | 18.9 | 18.9 |
| Axitinib | 11 | 18.8 | 18.8 |
| Encorafenib | 4 | 13.3 | 13.3 |
| Lenvatinib | 10 | 10.1 | 10.1 |
| Axicabtagene Ciloleucel | 3 | 10.0 | 10.0 |